Optellum’s existing technologies, Virtual Nodule Clinic and Lung Cancer Prediction AI, are FDA-cleared, CE-marked, and UKCA-marked medical devices with reimbursement in the US. They are deployed in health systems around the world, identifying patients with incidentally detected lung nodules and providing an AI-powered malignancy risk score that supports more stratification and better clinical decision-making.
With this foundation model, Optellum aims to expand its impact far beyond lung nodule management and risk prediction, accelerating discovery and delivering intelligent, scalable solutions for multiple thoracic diseases.
“Early detection saves lives. Too many patients are still diagnosed late and miss the best chance for curative treatment,” said Johnathan Watkins, PhD, CEO of Optellum. “In the US alone, over 125,000 people will die from lung cancer this year, and over 145,000 will die from chronic lower respiratory diseases – many without ever having been eligible for screening. By learning from one of the largest and most diverse thorax CT datasets in the world, and applying cutting-edge AI, we will equip clinicians and researchers with powerful tools to detect disease earlier, better guide precision treatment, and ultimately save more lives.”
Ad Statistics
Times Displayed: 0
Times Visited: 0 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
Building the future of AI-enabled clinical pathways
The project is driven by Optellum’s team of world-class AI researchers, in-house clinicians, and multi-disciplinary clinical advisors (including pulmonologists, radiologists, thoracic surgeons). The foundation model is supported by proprietary models, deep clinical experience, access to large, deidentified datasets, and deep partnerships with academic and clinical collaborators. Optellum has a culture of continuous improvement and welcomes further collaboration with hospitals, academic institutions, and forward-thinking investors who share the vision for equitable, intelligent, and scalable lung health care.
About Optellum
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.
Optellum’s flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world’s first and only FDA-cleared and reimbursable software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum’s solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians’ efficiency, reducing time to guideline-recommended treatment. Optellum VNC is FDA cleared, CE-MDR marked, and UKCA marked.
Optellum is headquartered in Oxford, UK, and has an office at the Texas Medical Center in Houston, Texas, US.
Back to HCB News
